**5. Conclusions**

In conclusion, we observed the clinically important improvement of both office blood pressure control and central aortic pressure parameters, including augmentation index, in half of our cohort of HCV-infected stable kidney transplant recipients after successful HCV eradication with a sofosbuvir-based DAA therapy. The concomitant decrease of liver steatosis, measured by the controlled attenuation parameter, was only observed in this subgroup of patients, which may sugges<sup>t</sup> the potential underlying mechanism of beneficial hemodynamic changes. Further investigation would elucidate the pathomechanism of the observed improvement of blood pressure control, however, the increased availability of DAA therapy already resulted in pretransplant eradication of HCV infection in a majority of currently dialysis patients. We believe that patients receiving DAA therapy in the pretransplant period will benefit even more. Nevertheless, the confirmation of relatively moderate BP improvement in dialysis patients would be much more difficult due to procedural-related fluctuations in volemia.

**Supplementary Materials:** The following are available online at http://www.mdpi.com/2077-0383/9/4/948/s1, Table S1: Laboratory parameters before and after successful DAA therapy, divided into subgroups based on changes in OBP control after treatment, Table S2: The results of liver function tests as well as the measurements of liver stiffness (LSM) and liver steatosis (controlled attenuation parameter—CAP) in kidney transplant recipients before and after the successful DAA therapy, divided into 2 subgroups based on the changes in OBP control after treatment.

**Author Contributions:** Conceptualization and methodology, A.K. and J.M.; formal analysis, A.K. and J.C.; investigation, M.B., N.S.-B., A.K.-S., and P.K.; data curation, A.K. and K.K.-F.; writing—original draft preparation, A.K., J.M., and J.C.; writing—review and editing, A.W.; supervision, A.K. and A.W.; funding acquisition, A.K. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by Medical University of Silesia in Katowice, Grant KNW-1-058/N/8/K.

**Conflicts of Interest:** The authors declare no conflict of interest.
